Solara Active Pharma Sciences
- P/E
- 91.22
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 4.86%
- Debt to Equity
- 0.41
- EPS (TTM)
- ₹7.07
- Book Value
- ₹295.98
- Market Cap
- —
- P/E (TTM)
- 91.22
- P/B
- 2.18
- ROE
- −0.13%
- Dividend Yield
- 0.48%
- EBITDA
- ₹193 Cr
- 52W High
- ₹774.00
- 52W Low
- ₹422.00
- Day Range
- ₹618.70 – ₹650.00
- Volume
- 1,07,612
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Solara Active Pharma Sciences (this company) | ₹644.90 | 91.22 | ₹3,038 Cr | 2.18 | 0.48% | −0.13% | 4.86% | ₹1,535 Cr | ₹37 Cr |
| Median 8 companies | ₹1,587.70 | 58.71 | ₹1,25,337 Cr | 4.57 | 0.53% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 49
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 56
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 87
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 25
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 57
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 41
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.27% over past five years.
- Company has a low return on equity of -12.0% over last 3 years.
- Promoters have pledged 37.1% of their holding.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Neutral | 6 | 7 | 6 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bearish
Overall
Neutral
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 47.64
- Neutral
- MACD (12,26,9)
- −10.43
- Bearish
- SMA (50)
- 673.29
- Bearish
- SMA (200)
- 556.05
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 5Y | −3.28% |
|---|---|
| 3Y | −1.76% |
| 1Y | +6.62% |
| TTM | +27.28% |
Net profit
| 5Y | Turned to loss |
|---|---|
| 3Y | Loss narrowed by ₹15 Cr |
| 1Y | Turned to loss |
| TTM | +428.57% |
Operating cash flow
| 5Y | −0.26% |
|---|---|
| 3Y | −0.65% |
| 1Y | −28.17% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −10.21 pp |
|---|---|
| 3Y | +4.38 pp |
| 1Y | −2.38 pp |
| TTM | −0.93 pp |
Revenue by year
| Mar 2018 | ₹521 Cr |
|---|---|
| Mar 2019 | ₹1,387 Cr |
| Mar 2020 | ₹1,322 Cr |
| Mar 2021 | ₹1,617 Cr |
| Mar 2022 | ₹1,268 Cr |
| Mar 2023 | ₹1,444 Cr |
| Mar 2024 | ₹1,289 Cr |
| Mar 2025 | ₹1,284 Cr |
| Mar 2026 | ₹1,369 Cr |
Net profit by year
| Mar 2018 | ₹0.00 Cr |
|---|---|
| Mar 2019 | ₹59.00 Cr |
| Mar 2020 | ₹115 Cr |
| Mar 2021 | ₹221 Cr |
| Mar 2022 | −₹58.00 Cr |
| Mar 2023 | −₹22.00 Cr |
| Mar 2024 | −₹567 Cr |
| Mar 2025 | ₹1.00 Cr |
| Mar 2026 | −₹7.00 Cr |
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 | 417 |
| Expenses | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 | 340 |
| Operating Profit | 38 | −162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 | 77 |
| OPM % | 9% | −76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% | 18% |
| Other Income | −4 | −62 | −120 | 1 | 0 | 1 | 6 | 1 | 0 | −7 | 4.69 | 3 | −4 |
| Interest | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 | 18 |
| Depreciation | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 | 27 |
| PBT | −17 | −275 | −167 | −13 | 8 | 8 | −2 | 11 | −10 | −17 | 10 | 16 | 28 |
| Tax % | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −17 | −275 | −255 | −13 | 8 | 8 | −2 | 11 | −10 | −17 | 10 | 16 | 28 |
| EPS (₹) | −3.58 | −57.36 | −53.2 | −3.74 | 2.22 | 2.24 | −0.58 | 2.91 | −2.79 | −4.82 | 2.65 | 3.38 | 5.86 |
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,535 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,301 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | −95 | 206 | 187 | 234 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | −7% | 16% | 14% | 15% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | −185 | 8 | 0 | −2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 89 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 105 |
| PBT | 0 | 60 | 115 | 222 | −91 | −45 | −488 | 1 | −7 | 37 |
| Tax % | −70% | 1% | 0% | 0% | −36% | −50% | 16% | 0% | 0% | — |
| Net Profit | 0 | 59 | 115 | 221 | −58 | −22 | −567 | 1 | −7 | 37 |
| EPS (₹) | — | 17.3 | 32.01 | 46.22 | −12.11 | −4.62 | −118 | 0.15 | −2.05 | 7.07 |
| Div. Payout % | 0% | 22% | 5% | 11% | 0% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 | 48 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 | 1,388 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 | 591 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 | 427 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 | 2,454 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 | 1,201 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 | 208 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 | 3 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 | 1,043 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 | 2,454 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 49 | 166 | 242 | 155 | −242 | 156 | 109 | 213 | 153 |
| Investing | −85 | −113 | −359 | −106 | −243 | −81 | −4 | −37 | −99 |
| Financing | 68 | −23 | 97 | 92 | 334 | −113 | −106 | −180 | −54 |
| Net Cash Flow | 31 | 30 | −20 | 142 | −151 | −38 | 0 | −4 | 1 |
| Free Cash Flow | 14 | 108 | −25 | −16 | −451 | 46 | 69 | 173 | 101 |
| CFO/EBITDA | 92 | 85 | 103 | 49 | −277 | 106 | −113 | 104 | 83 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 144 | 146 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 134 | 140 |
| Working Capital Days | −124 | −22 | −32 | 16 | 37 | 20 | −128 | −62 | −24 |
| ROCE % | — | 10% | 12% | 15% | 0% | 2% | −9% | 6% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Solara Active Pharma Sciences insights
70 extracted metrics across FY17–FY27.
Documents
- Concall · Oct 2026Recording
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 22 Jun 2026
- 30 Apr 2026
- 16 Apr 2025
- 7 Jun 2024
- 3 May 2024
- General announcements 17 Oct 2026
Frequently Asked Questions about Solara Active Pharma Sciences
What does Solara Active Pharma Sciences Ltd do?
Where is Solara Active Pharma Sciences Ltd (SOLARA) listed?
Which sector does Solara Active Pharma Sciences Ltd belong to?
What is the PE ratio of Solara Active Pharma Sciences Ltd?
What is the 52-week high and low of Solara Active Pharma Sciences Ltd?
Does Solara Active Pharma Sciences Ltd pay dividends?
What is the Return on Equity (ROE) of Solara Active Pharma Sciences Ltd?
Company Information
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SOLARA.md for Solara Active Pharma Sciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.